REPROXALAP
Sjogren-Larsson Syndrome
Aldeyra Therapeutics, Inc.Small moleculePhase 3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Sjogren-Larsson Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Adx-629 University of Nebraska | Phase 1/2 | CCC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →